Psychiatry

Our team is adept at ensuring data quality in these complex scenarios, utilising expert psychiatric evaluators and advanced data capture technologies.

Mental health clinical trials pose challenges from multiple perspectives. A CRO must ensure that it has the requisite skills to allow recruitment of the correct population, minimise placebo effects, standardise (subjective) rating scales, and ensure patient safety.

Our expertise extends to various conditions, including:
  • Depression
  • Anxiety Disorders
  • Schizophrenia
  • Bipolar Disorder
  • Psychedelic Clinical Trials, where we are considered global leaders

We help design studies that consider the unique nature of psychiatric assessments, which often rely on patient-reported outcomes and observer ratings. Strategies to minimise placebo effect and neurobehavioural biases are always built into all our mental health trials.

Our team is adept at ensuring data quality in these complex scenarios, utilizing expert psychiatric evaluators and advanced data capture technologies.

Our expertise extends to various conditions, including:
psychiatry icons_depression icon-iNGENū CRO
psychiatry icons_anxiety icon-iNGENū CRO
psychiatry icons_schizo icon-iNGENū CRO
psychiatry icons_bipolar icon-iNGENū CRO
psychiatry icons_psychedelic icon-iNGENū CRO

We help design studies that consider the unique nature of psychiatric assessments, which often rely on patient-reported outcomes and observer ratings. Strategies to minimize placebo effect and neurobehavioral biases are always built into all our mental health trials.

Our clinical team has over

120

years of combined clinical trial experience

Access up to

43.5%

Government R&D tax incentive (even for foreign companies)

Fast start-up

8-12

weeks on average, without sacrificing quality

Pain points associated with clinical trials in psychiatry

  • Subjectivity of Assessments: Many psychiatric symptoms are self-reported, leading to potential biases and variability in data.
  • Heterogeneity of Disorders: There's often a wide range of symptoms within a single diagnosis, which can make it hard to ascertain treatment effects for a broad population.
  • Placebo Effect: Psychiatric trials often have a strong placebo response, making it difficult to demonstrate the efficacy of the investigational treatment.
  • Recruitment Challenges: It can be challenging to recruit and retain participants for psychiatric studies due to stigma, severity of illness, or concerns about novel treatments.
  • Ethical Concerns: Balancing the potential risks and benefits, especially in vulnerable populations or with novel treatments, can be challenging.

How iNGENū addresses these pain points

  • Objective Biomarkers: One of our flagship initiatives involves advancing the quest for objective biomarkers. Recognising the challenges of subjective assessments, iNGENū is collaborating with experts to develop and implement imaging techniques and blood tests that promise a more objective measure for psychiatric disorders and treatment responses.
  • Stratified and Personalised Medicine: Recognising that not all patients with the same diagnosis are alike, we aim to pinpoint patient profiles and specific subtypes of disorders, enabling the development of tailored therapeutic interventions that yield better outcomes.
  • Adaptive Trial Designs: We are actively promoting and utilising adaptive trial designs. By allowing for real-time modifications based on emerging results, these trials are not only more efficient but also have the potential to be more patient-centric, addressing the challenges of the strong placebo effects often seen in psychiatric research.
  • Patient Engagement: iNGENū collaborates closely with patient groups to ensure that trials are designed with the patients' needs and concerns at the forefront, thereby enhancing recruitment and retention rates.

Psychiatry Clinical Trial Resources

iNGENu_ADHD

ADHD

Bridging the Past and Future of Treatment Strategies. From pivotal endpoints to enhancing trial success.

Bipolar Disorder

Bipolar Disorder

Read our whitepaper on epidemiology, clinical implications, and strategies for clinical trial success.

Schizophrenia-1

Schizophrenia

Evolving Insights into Schizophrenia Diagnosis and Treatments. Understanding clinical trial strategies.

The iNGENū CRO Difference

Expertise
Expertise from the Start

At iNGENū CRO, you engage directly with experienced specialists from the outset. Our team, comprised of highly qualified doctors and PhD scientists, provides immediate, accurate answers to your complex inquiries, ensuring efficiency and clear communication.

Drug Dev Plans
Highly Customised Drug Development Plans

iNGENū CRO stands out for our ability to create highly customised drug development plans. Our experienced team leverages their extensive background in standard and non-standard pharmaceutical practices to develop innovative and unique solutions tailored to your specific drug.

Service Offering
Full Service CRO

We provide a full range of services from preclinical research through Phase 1, 2, and 3 clinical trials. Unlike other CROs that may outsource certain stages or recommend third-party vendors, iNGENū CRO handles everything in-house.

"We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug. We have used iNGENū for: Medical writing, project management, clinical data management and full end-to-end, clinical trial execution and monitoring.

We have been very happy with all aspects of the management of the clinical trial and have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads for our company during this clinical trial."

Giles Moss
Chief Executive Officer

iNGENu testimonial-logos-monotone-1

Ready to discuss your Psychiatry Clinical Trial?